Complement C5 Inhibitors & C5 Receptor Antagonists Pipeline Competitor Analysis Report 2026: Active R&D Programs by R&D Phase and Profile of Targeted Immunotherapies by Drug ...

Emerging opportunities in the C5 inhibitor market include advances in biosuperiors and biosimilars, targeting a range of C5-mediated diseases such as PNH and aHUS. Innovations focus on enhancing ...
Nature

Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1

As a crucial arm of innate immunity, the complement cascade (ComC) is involved both in mobilization of normal hematopoietic stem/progenitor cells (HSPCs) from bone marrow (BM) into peripheral blood ...

InflaRx Highlights Favorable Safety-Signal Data for Izicopan in New Preclinical Study

InflaRx ( (IFRX)) has provided an announcement. On May 4, 2026, InflaRx reported new preclinical data showing that its investigational C5aR1 inhibitor izicopan generates minimal reactive metabolites ...

InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript

Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases May 8, 2026 8:30 AM EDTCompany ...